RAS mutations have been described as a potential mechanism of resistance to mutant IDH inhibitor treatment32 and identification of these mutant clones in a pre-clinical MDS PDX may thus guide the use of pre-emptive combination regimens. Here, IDH2 is linked to myelodysplastic syndrome.